Acarix AB (FRA:7AC) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7AC Acarix AB FRA:7AC
44 GF Score
Price €0.02
GF Value €0.01
! 1 Warning Sign
View Full Analysis

What is Acarix AB Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:7AC
44GF Score
Acarix AB FRA:7AC
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Acarix AB (FRA:7AC) Overvalued in 2026?

Based on GuruFocus' analysis, Acarix AB stock appears to be overvalued. The current stock price of €0.02 is trading 54% above its estimated GF Value™ of €0.01.

Key valuation signals for FRA:7AC:

  • Short Ratio:
  • GF Value™: €0.01 vs. price of €0.02 (54% above fair value)
  • GF Score™: 44/100 with 1 warning sign

No single metric tells the full story. See the FRA:7AC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Acarix AB Business Description

Other Exchanges ACIXF:USAACARIX:Sweden
Address Hyllie Boulevard 34, Regus Malmo, Malmo, SWE, 215 32
Acarix AB is a Swedish medical technology company that develops solutions for rapid AI-based exclusion of coronary artery disease (CAD). Its CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. Acarix recommends the CADScor System as a first-line diagnostic tool that uses sensitive acoustics and computational processing to analyze coronary blood flow to rule out coronary artery disease (CAD), with a majority certainty at the point of care. Geographically, the company generates maximum revenue from the United States, and the rest from Germany, Sweden, Iraq, and other regions.
44GF Score

Get the complete analysis for FRA:7AC

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.02
Price
€0.01
GF Value